Analysts Set Expectations for ADAP Q1 Earnings

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Adaptimmune Therapeutics in a note issued to investors on Tuesday, March 25th. Leerink Partnrs analyst J. Chang anticipates that the biotechnology company will earn ($0.10) per share for the quarter. The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.14) per share. Leerink Partnrs also issued estimates for Adaptimmune Therapeutics’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.35) EPS and FY2026 earnings at ($0.11) EPS.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings results on Monday, March 24th. The biotechnology company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.09). The firm had revenue of $3.22 million for the quarter, compared to analysts’ expectations of $16.56 million. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%.

A number of other research analysts have also recently commented on the stock. Wells Fargo & Company decreased their target price on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a research report on Friday, March 21st. Scotiabank dropped their target price on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a report on Friday, March 21st. StockNews.com initiated coverage on Adaptimmune Therapeutics in a research note on Friday, March 21st. They set a “buy” rating on the stock. Finally, Guggenheim dropped their price objective on Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating for the company in a research note on Wednesday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1.93.

Adaptimmune Therapeutics Stock Performance

Shares of Adaptimmune Therapeutics stock opened at $0.22 on Friday. The firm has a market cap of $56.29 million, a PE ratio of -1.00 and a beta of 2.52. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. Adaptimmune Therapeutics has a 52 week low of $0.22 and a 52 week high of $1.65. The business’s fifty day simple moving average is $0.51 and its 200-day simple moving average is $0.68.

Institutional Trading of Adaptimmune Therapeutics

Several hedge funds have recently modified their holdings of ADAP. FMR LLC grew its stake in Adaptimmune Therapeutics by 3.0% during the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock worth $1,655,000 after purchasing an additional 50,419 shares in the last quarter. Jane Street Group LLC grew its position in shares of Adaptimmune Therapeutics by 130.4% during the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after buying an additional 98,581 shares in the last quarter. Virtu Financial LLC increased its stake in shares of Adaptimmune Therapeutics by 27.5% during the third quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock worth $96,000 after buying an additional 21,769 shares during the period. LPL Financial LLC lifted its stake in Adaptimmune Therapeutics by 106.5% in the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 94,623 shares during the last quarter. Finally, Invesco Ltd. increased its position in shares of Adaptimmune Therapeutics by 82.0% in the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 28,526 shares during the last quarter. 31.37% of the stock is currently owned by institutional investors and hedge funds.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.